Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12337678 | 0.88 | ALDH1A1 (0.39) | TRPA1ALDH1A1TSHRSMN1; SMN2CHKA | |
| SCHEMBL21345261 | 0.82 | IDO1 (0.52) | — | |
| SCHEMBL7561792 | 0.82 | TSHR (0.48) | TRPA1ALDH1A1TSHRHPGDCES2 | |
| SCHEMBL131361 | 0.80 | ALDH1A1 (0.67) | TRPA1ALDH1A1TSHRCES2CES1 | |
| SCHEMBL385188 | 0.78 | SLC6A4 (0.52) | TRPA1ALDH1A1TSHRMAPTMEN1 | |
| SCHEMBL21088432 | 0.78 | TRPA1 (0.43) | TRPA1ALDH1A1TSHRCES2CES1 | |
| SCHEMBL9303786 | 0.78 | TRPA1 (0.43) | TRPA1ALDH1A1TSHRCES2CES1 | |
| SCHEMBL21545797 | 0.77 | EHMT2 (0.59) | TRPA1ALDH1A1TSHRMAPTHPGD | |
| SCHEMBL10996987 | 0.76 | SLC6A4 (0.50) | TRPA1ALDH1A1TSHRMAPTMEN1 | |
| SCHEMBL6180311 | 0.74 | ALDH1A1 (0.59) | TRPA1ALDH1A1TSHRMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112592406-B | Fixed-point conjugate of anti-CD 24 antibody and diethylazo-onium dialkoxide molecule and application thereof | 中国药科大学 | 2023-07-11 | — | — | CN | disclosed |
| CN-108047086-B | Compositions containing unnatural amino acids and polypeptides, methods involving unnatural amino acids and polypeptides, and uses thereof | AMBRX公司 | 2023-06-16 | — | — | CN | disclosed |
| WO-2019169953-A1 | CD24-TARGETING MONOCLONAL ANTIBODY AND DIETHYLAMINE AZO ONIUM DIOL SALT CONJUGATE AND USE THEREOF | 中国药科大学 | 2019-09-12 | — | — | WO | disclosed |
| US-9637441-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637441-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-2528901-B9 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-1828224-B1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX INC (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-1828224-B1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX INC (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2528901-B1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-20150094457-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-7385028-B2 | Modified non-natural amino acid polypeptides typically include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7385028-B2 | Modified non-natural amino acid polypeptides typically include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1828224-A2 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | Ambrx, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060217532-A1 | Incorporating a non-natural amino acid having oxime, carbonyl, dicarbonyl, and/or hydroxylamine group into a terminal or internal position within a polypeptide | AMBRX, INC. (US) | 2006-09-28 | — | — | US | disclosed |
| US-20060217289-A1 | Administering a polypeptide having an oxime-containing non-natural amino acid, from a translation system of: a polynucleotide comprising a selector codon encoding the polypeptide, a tRNA comprising the oxime-containing amino acid | AMBRX, INC. (US) | 2006-09-28 | — | — | US | disclosed |
| WO-2006069246-A9 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX INC (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060194256-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| WO-2006069246-A2 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194256-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | TRPA1 4544/4885ALDH1A1 2338/4885TSHR 1183/4885 |
| US-20150094457-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | TRPA1 4774/4885ALDH1A1 3172/4885TSHR 1876/4885 |
| US-20060217289-A1 | Administering a polypeptide having an oxime-containing non-natural amino acid, from a translation system of: a polynucleotide comprising a selector codon encoding the polypeptide, a tRNA comprising the oxime-containing amino acid | DAO, OSGEP, OTC | TRPA1 3967/4885ALDH1A1 3570/4885TSHR 732/4885 |
| US-20060217532-A1 | Incorporating a non-natural amino acid having oxime, carbonyl, dicarbonyl, and/or hydroxylamine group into a terminal or internal position within a polypeptide | DAO, DNPEP, PTMS | TRPA1 4736/4885ALDH1A1 2529/4885TSHR 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.